This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study
by Zacks Equity Research
Akari (AKTX) presents favorable safety data from part A of an early-stage study on nomacopan for treating moderate to severe atopic keratoconjunctivitis. Shares appreciate.
Intrexon Up on Striking 100M Cannabinoid Deal With Surterra
by Zacks Equity Research
Intrexon (XON) inks a $100-million worth exclusive licensing deal with Surterra to produce cannabinoid in a reliable and cost-effective fashion, using its own yeast fermentation process. Shares climb.
Wall Street Foresees a Fed Rate Cut: Winners & Losers
by Tirthankar Chakraborty
Some analysts have started to price in "insurance cuts," which means they are expecting the Fed to cut rates right before a downturn in order to save the economy.
NuCana's Biliary Tract Cancer Candidate Gets Orphan Drug Tag
by Zacks Equity Research
The FDA confers an orphan drug designation on NuCana's (NCNA) pipeline candidate, Acelarin, for treating patients with biliary tract cancer
Denali's Hunter Syndrome Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA assigns an orphan drug designation and a rare pediatric disease designation to Denali's (DNLI) pipeline candidate, DNL310, for treating patients with Hunter Syndrome. Shares inch up.
Athenex Rallies on Positive Early Data on Psoriasis Candidate
by Zacks Equity Research
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
Looking for a Growth Stock? 3 Reasons Why Repligen (RGEN) is a Solid Choice
by Zacks Equity Research
Repligen (RGEN) is well positioned to outperform the market, as it exhibits above-average growth in financials.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
by Zacks Equity Research
BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.
Reata's (RETA) Kidney Candidate Gets Orphan Drug Status
by Zacks Equity Research
The FDA bestows an orphan drug designation on Reata Pharmaceuticals' (RETA) candidate, bardoxolone, for treating patients with autosomal dominant polycystic kidney disease.
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex Pharmaceuticals, Gilead Sciences, Repligen, Illumina and Bio-Techne
Seattle Genetics, Astellas' Cancer Candidate Attains 44% ORR
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas post favorable data from the first cohort of a phase II study on enfortumab vedotin for treating advanced/metastatic urothelial cancer. Shares up as the candidate achieves 44% ORR.
5 Biotech Stocks to Buy Right Now
by Zachary Stutler
here are a few stocks that have outperformed their peers and are expected to have continued growth throughout the next couple of years. All the stocks in this list are a Zacks Rank #2 (Buy) or better.
The Zacks Analyst Blog Highlights: HEICO, Group 1 Automotive, Rent-A-Center, Repligen and Strategic Education
by Zacks Equity Research
The Zacks Analyst Blog Highlights: HEICO, Group 1 Automotive, Rent-A-Center, Repligen and Strategic Education
U.S. Heading for Largest Economic Expansion: 5 Top Picks
by Nalak Das
According to the National Bureau of Economic Research, the ongoing expansion started back in June 2009.
Mesoblast Starts Rolling BLA Submission for Remestemcel-L
by Zacks Equity Research
Mesoblast (MESO) begins the rolling submission of a BLA for its lead product, candidate remestemcel-L, to the FDA for treating children with steroid-refractory acute graft versus host disease.
Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems
by Zacks Equity Research
Zacks.com featured highlights include: Strategic Education, Repligen, Kinsale Capital, Arcosa and OSI Systems
3 Reasons Why Growth Investors Shouldn't Overlook Repligen (RGEN)
by Zacks Equity Research
Repligen (RGEN) could produce exceptional returns because of its solid growth attributes.
5 Stocks With Recent Price Strength Despite Trade Concerns
by Nalak Das
Investors target stocks that have been on a bullish run lately. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
Mallinckrodt Ends Enrollment in Phase III for Terlipressin
by Zacks Equity Research
Mallinckrodt (MNK) concludes enrollment in the phase III study on terlipressin, currently under development for treating adult patients with Hepatorenal Syndrome Type 1.
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 7.69% and 0.21%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Turtle Beach (HEAR) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Solid product performance and excellent market position, driven by innovation, quality products, strong brand and retail partnerships, are likely to drive Turtle Beach's (HEAR) first-quarter results.
Repligen (RGEN) Matches Q4 Earnings Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 0.00% and 3.20%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
ANIK vs. RGEN: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ANIK vs. RGEN: Which Stock Is the Better Value Option?
Repligen (RGEN) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Repligen (RGEN) delivered earnings and revenue surprises of 11.11% and 6.01%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?